The Pharmacy Care Alliance (PCA) today announced that AstraZeneca, Johnson & Johnson Pharmaceutical Companies, Inc., Eli Lilly and Company, Merck and Novartis will make many prescription drugs available to qualifying PCA Medicare discount cardholder
Roche OSI Pharmaceuticals and Genentech today announced that their investigational drug Tarceva(TM) (erlotinib) achieved a significant 42.5% improvement in median survival compared to placebo in patients with advanced non-small cell lung cancer (NSCLC).
Participants at the Susan G. Komen Breast Cancer Foundation National Race for the Cure? were among the first to view a new breast cancer ribbon today as they descended on the National Mall. More than 51,000 runners and walkers, more than including 3,500
Amylin Pharmaceuticals, Inc., and Eli Lilly and Company have presented detailed 30-week data from two of the three pivotal Phase 3 studies of exenatide during a late-breaking session
Clinicians from the McGill University Health Centre and the Centre hospitalier de l'Université de Montréal (CHUM) are participating in the first Canadian therapeutic HIV vaccine trial. Funded by a number of public and private institutions,
Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the s
A new multi-targeted anticancer drug called SU11248 has shown very promising results in the treatment for metastatic renal cell cancer, one of the most chemotherapy resistant of all cancers. The study's lead investigator, Robert Motzer, MD, attending physi
Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study presented today at the American Society of Cli
New research presented by Peter Weissman, M.D., from the University of Miami, at the 64th Annual Scientific Sessions of the American Diabetes Association shows that combination treatment with rosiglitazone maleate and metformin significantly improves ce
Patients with Type 2 diabetes and a CV risk factor would benefit from a cholesterol-lowering medicine according to results from the first ever specifically designed UK primary prevention statin trial announced today at the American Diabetes Association
Contrary to what Patrick Sullivan, Ph.D, of the University of Colorado School of Pharmacy, and colleagues expected, patients did not turn to other prescription drugs for allergies and asthma or to antibiotics in greater numbers after loratadine lost its prescription-only status.
"Instead, there were fewer prescriptions and lower costs for all drugs across the board," Sullivan says.
The decrease in costs occurred across all types of plans, regardless of whether loratadine was covered as a "preferred" drug, the researchers say.
Insurance plans may have saved money after Claritin's switch to OTC status in part because physicians wrote fewer prescriptions for antihistamines, the researchers found.
"Consumers appear to have benefited as well," Sullivan says, noting that the price of what had been the world's most-prescribed antihistamine is now lower than the average copayment for prescription antihistamines before the switch.
This class of drugs also includes cetirizine (Zyrtec) and fexofenadine (Allegra). The drugs treat seasonal allergies and chronic nasal congestion without some of the side effects, such as drowsiness, of early antihistamines.
When loratadine became an over-the-counter product in December 2002, some insurance plans moved the drug into their third tier of coverage, a group of brand name drugs that have an effective and less costly generic equivalent. Third-tier drugs generally have the highest prescription costs and copayments within an insurance plan.
Other plans made no change to loratadine's status, while other sponsors, including many Medicaid managed care plans, offered loratadine under its original prescription status only to patients who had been prescribed the drug prior to its OTC switch.
A year after any plan changes, patients with third-tier coverage for second-generation antihistamines paid $11.40 more a prescription. Those under restricted plans paid $1.70 less a prescription, while there was no change in price under plans that kept the same coverage.
When Sullivan and colleagues calculated copayment costs based on how many prescriptions each person filled a month, however, average copayment costs fell 23 percent in third-tier plans and 46 percent to 64 percent in the no-change and restricted plans.
The difference may be a result of patients obtaining fewer prescriptions for the drugs. The average number of prescriptions filled for each person a month fell at least 46 percent during the study, the researchers found.
Sullivan says it is possible that allergy patients "were able to obtain adequate treatment with over-the-counter loratadine and had less need to contact the health plan for the treatment of their primary condition."
The researchers say it is unclear whether patients who used fewer prescription second-generation antihistamines treated themselves properly with OTC loratadine, or whether they turned in greater numbers to older OTC drugs such as Benadryl.
"This effect would be detrimental to society and should be examined in future research," Sullivan and colleagues say.
The study was supported by a grant from Schering-Plough, the makers of Claritin.
http://www.hbns.org